



**Clinical Policy: Denosumab (Xgeva), Denosumab-bbdz (Jubbenti, Wyost)**

Reference Number: LA.PHAR.58

Effective Date: 04.21

Last Review Date: ~~10.04.24~~ 05.07.24

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

Formatted Table

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

**Description**

Denosumab (Xgeva®) ~~is and its biosimilars, denosumab-bbdz (Jubbenti®-Wyost®), are~~ receptor ~~activator~~ activators of nuclear factor kappa-B ligand inhibitor.

**FDA Approved Indication(s)**

Xgeva ~~is indicated~~ and Wyost are indicated:

- For the prevention of skeletal-related events in patients with multiple myeloma (MM) and in patients with bone metastases from solid tumors.
- For the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
- For the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

## CLINICAL POLICY

### Denosumab



#### Index

##### I. Initial Approval Criteria

- ~~A. Osteoporosis (Prolia or Jubbonti)~~
- ~~B. Prostate/Breast Cancer Fracture Prevention (Prolia or Jubbonti)~~
- ~~C.A. Multiple Myeloma or Solid Tumor (Xgeva or Wyost)~~
- ~~D.B. Giant Cell Tumor of Bone (Xgeva or Wyost)~~
- ~~E.C. Hypercalcemia of Malignancy (Xgeva or Wyost)~~
- ~~F.D. Systemic Mastocytosis (off-label) (Xgeva or Wyost)~~
- ~~G.E. Other diagnoses/indications~~

**Commented [ER1]:** Removing these conditions from the Index, as they only apply to Prolia and its biosimilars, which aren't applicable to this policy. State PDL Policy used for Prolia

##### II. Continued Therapy

- A. All Indications in Section I (~~Xgeva~~, ~~and Wyost~~)
- B. Other diagnoses/indications

##### III. Diagnoses/Indications for which coverage is NOT authorized

##### IV. Appendices/General Information

##### V. Dosage and Administration

##### VI. Product Availability

##### VII. References

It is the policy of Louisiana Healthcare Connections that Xgeva and Wyost ~~is~~ **are medically necessary** when the following criteria are met:

##### I. Initial Approval Criteria

###### A. Multiple Myeloma or Solid Tumor (must meet all):

1. Request is for Xgeva or Wyost;
2. Diagnosis of one of the following (a or b):
  - a. MM, and member is receiving or initiating therapy (e.g., chemotherapy, transplant) for symptomatic disease;
  - b. Bone metastasis secondary to solid tumor (e.g., breast, kidney, lung, prostate, thyroid);
3. Prescribed by or in consultation with an oncologist;
4. Age  $\geq$  18 years or documentation of closed epiphyses on x-ray;
5. For indications other than prostate or breast cancer, member meets ~~one of the following (a or b):~~
  - a. Failure of zoledronic acid\* (Zometa) or pamidronate\* at up to maximally indicated doses, unless clinically significant adverse effects are experienced or both are contraindicated (*see Appendices B and D*);  
*\*Prior authorization may be required.*
  - ~~b. Request is for the treatment associated with stage IV or metastatic cancer for a state with regulations against step therapy in advanced certain oncology settings (see Appendix E);~~
6. Xgeva ~~is or Wyost are~~ not prescribed concurrently with Prolia or Jubbonti;
7. Dose does not exceed 120 mg every 4 weeks.

**Approval duration:** 6 months

**Formatted:** Font: Bold

###### B. Giant Cell Tumor of Bone (must meet all):

## CLINICAL POLICY

### Denosumab



1. Request is for Xgeva or Wyost;
2. Diagnosis of giant cell tumor of bone that is characterized as one of the following (a or b):
  - a. Metastatic or unresectable disease;
  - b. Localized disease, and Xgeva is prescribed as a single agent or in combination with interferon alfa or radiation therapy;
3. Prescribed by or in consultation with an oncologist;
4. Age  $\geq$  18 years or documentation of closed epiphyses on x-ray;
5. Xgeva ~~is or Wyost are~~ not prescribed concurrently with Prolia or Jubbonti;
6. Dose does not exceed 120 mg every 4 weeks plus 120 mg on days 8 and 15 of first month of therapy.

**Approval duration:** 6 months

Formatted: Font: Bold

Formatted: Font: Not Bold, Font color: Purple

#### C. Hypercalcemia of Malignancy (must meet all):

1. Request is for Xgeva or Wyost;
2. Diagnosis of hypercalcemia of malignancy;
3. Prescribed by or in consultation with an oncologist;
4. Age  $\geq$  18 years or documentation of closed epiphyses on x-ray;
5. Albumin-corrected calcium  $>$  12.5 mg/dL despite IV bisphosphonate therapy in the last 30 days (*see Appendix B*);  
*\*Prior authorization may be required.*
6. Xgeva ~~is or Wyost are~~ not prescribed concurrently with Prolia or Jubbonti;
7. Dose does not exceed 120 mg every 4 weeks plus 120 mg on days 8 and 15 of first month of therapy.

**Approval duration:** 6 months

Formatted: Font: Bold

Formatted: Font: Not Bold, Font color: Purple

#### D. Systemic Mastocytosis (off-label) (must meet all):

1. Request is for Xgeva or Wyost;
2. Diagnosis of systemic mastocytosis;
3. Member has osteopenia or osteoporosis with bone pain;
4. Prescribed by or in consultation with an oncologist;
5. Age  $\geq$  18 years or documentation of closed epiphyses on x-ray;
6. Member meets ~~one of the following (a or b):~~
  - a. Failure of zoledronic acid\* (Zometa) or pamidronate\* at up to maximally indicated doses unless clinically significant adverse effects are experienced or both are contraindicated (*see Appendices B and D*);  
*\*Prior authorization may be required.*
  - ~~b. Request is for the treatment associated with Stage IV or metastatic cancer for a State with regulations against step therapy in advanced certain oncology settings (*see Appendix E*);~~
7. Xgeva ~~is or Wyost are~~ not prescribed concurrently with Prolia or Jubbonti;
8. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).\*

*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

**Approval duration:** 6 months

Formatted: Keep with next

Formatted: Font: Bold

Formatted: Font: Not Bold, Font color: Purple

Formatted: Font color: Auto

Formatted: Tab stops: Not at 2.68"

**~~A-E.~~ Other diagnoses/indications (must meet 1 or 2):**

- ~~1.~~ **~~a.~~** If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy **for the relevant line of business**: LA.PMN.53 for Medicaid.

Formatted: Font: Not Bold, Font color: Auto

Formatted: Indent: Left: 0.25", Numbered + Level: 2 + Numbering Style: A, B, C, ... + Start at: 1 + Alignment: Left + Aligned at: 0.31" + Indent at: 0.56"

Formatted: Font color: Auto

Formatted: Font: Not Bold, Font color: Auto

Formatted: Indent: Left: 0.75"

**II. Continued Therapy**

**~~B-A.~~ All Indications in Section I (must meet all):**

1. Member meets one of the following (a or **b**):
  - a. Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
  - b. Documentation supports that member is currently receiving **~~Prolia~~Xgeva~~;~~** **~~Jubbonti~~** or **Wyost** for a covered cancer-related indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
- 3.** If request is for a dose increase, new dose does not exceed ~~(a or b):~~
  - a. **Xgeva or Wyost**: 120 mg every 4 weeks or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).\*

*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

**Approval duration: 12 months**

Formatted: Font: Bold

**~~A-B.~~ Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy **for the relevant line of business**: LA.PMN.53 **for Medicaid**.

Formatted: Font color: Purple

Formatted: Tab stops: 2.68", Left

Formatted: Font color: Text 1

Formatted: Indent: Left: 0.25", Numbered + Level: 1 + Numbering Style: A, B, C, ... + Start at: 1 + Alignment: Left + Aligned at: 0.75" + Indent at: 1"

Formatted: Font: Bold, Font color: Text 1

Formatted: Font color: Text 1

Formatted: Font: Bold, Font color: Text 1

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

ADT: androgen deprivation therapy

BMD: bone mineral density

FDA: Food and Drug Administration

GIO: glucocorticoid-induced osteoporosis

MM: multiple myeloma

PMO: postmenopausal osteoporosis

#### Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent ~~for all relevant lines of business~~ and may require prior authorization.

Formatted: Keep with next

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<b>IV bisphosphonates</b>		
ibandronate (Boniva®)	Treatment: PMO Hypercalcemia of malignancy ( <i>off-label</i> )	Varies <i>See prescribing information and compendia for dosing.</i>
zoledronic acid (Reclast®; Zometa®)	<u>Reclast:</u> Treatment/prevention: PMO, GIO Treatment: male osteoporosis <u>Zometa:</u> MM Bone metastasis from solid tumors Hypercalcemia of malignancy Systemic mastocytosis ( <i>off-label</i> ) Fracture prevention - breast/prostate cancer ( <i>off-label</i> )	
pamidronate	MM Bone metastasis from breast cancer Hypercalcemia of malignancy Systemic mastocytosis ( <i>off-label</i> ) Fracture prevention – breast/prostate cancer ( <i>off-label</i> )	
<b>Oral bisphosphonates</b>		
alendronate (Fosamax®)	Treatment: PMO Treatment: GIO, male osteoporosis	Varies <i>See prescribing information and compendia for dosing.</i>
Fosamax® Plus D (alendronate / cholecalciferol)	Treatment: PMO, male osteoporosis	
risedronate (Actonel®, Atelvia®)	<u>Actonel:</u> Treatment: PMO, GIO Treatment: male osteoporosis <u>Atelvia:</u> Treatment: PMO	
ibandronate (Boniva®)	Treatment/prevention: PMO	

Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.

#### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Xgeva and Wyost: hypocalcemia, known clinically significant hypersensitivity to Xgeva or Wyost
- Boxed warning(s): none reported

*Appendix D: IV/PO Bisphosphonates: Examples of Contraindications and Adverse Effects*

Bisphosphonates	Oral Formulations	IV Formulations
<b>Contraindications</b>		
Hypocalcemia	X	X
Increased risk of aspiration	X	-
Hypersensitivity to product component	X	X
Inability to stand/sit upright for at least 30 minutes	X	-
Creatinine clearance < 35 mL/min or evidence of acute renal impairment	-	X
Esophagus abnormalities which delay emptying such as stricture or achalasia	X	-
<b>Clinically significant warnings or adverse side effects</b>		
Pregnancy	X	X
Eye inflammation	X	X
Acute renal failure	X	X
Osteonecrosis of the jaw	X	X
Atypical femoral shaft fracture	X	X
Drug interactions (product-specific)	X	X
Severe or incapacitating musculoskeletal pain	X	X

*Appendix E: States with Regulations against Redirections in Stage III, IV or Metastatic Cancer*

State	Step-Therapy Prohibited?	Notes
LA	Yes	<del>For stage 4 advanced, metastatic cancer or associated conditions. Exception if "clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.</del>

**V. Dosage and Administration**

Drug Name	Indication	Dosing Regimen	Maximum Dose
Denosumab (Xgeva, Wvost)	MM	120 mg SC once every 4 weeks	20 mg/dose
	Solid tumor - bone metastasis		
	Giant cell tumor of bone Hypercalcemia of malignancy	120 mg SC every 4 weeks plus 120 mg on Days 8 and 15 of first month of therapy	120 mg/dose

**VI. Product Availability**

Drug Name	Availability
Denosumab (Xgeva, Wyost)	Injection (single-use vial): 120 mg/1.7 mL (70 mg/mL)

## VII. References

Formatted: Indent: Hanging: 0.31", Keep with next

1. Prolia Prescribing Information. Thousand Oaks, CA: Amgen Inc.; January 2023. Available at: <http://www.prolia.com>. Accessed October 23, 2023.
2. Jubbonti Prescribing Information. Princeton, NJ: Sandoz Inc.; March 2024. Available at: <http://www.jubbonti.com>. Accessed March 13, 2024.
3. Xgeva Prescribing Information. Thousand Oaks, CA: Amgen Inc.; June 2020. Available at: <http://www.xgeva.com>. Accessed October 23, 2023.
4. Wyost Prescribing Information. Princeton, NJ: Sandoz Inc.; March 2024. Available at: <http://www.wyost.com>. Accessed March 13, 2024.
5. Clinical Pharmacology [database online]. Tampa, FL: Elsevier. 2023. URL: [www.clinicalkeys.com/pharmacology](http://www.clinicalkeys.com/pharmacology).
6. *Osteoporosis Diagnosis, Fracture Risk, and Treatment*
7. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. *J Clin Endocrinol Metab*; March 2020, 105(3): 587-594.
8. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*; 2019, 104: 1595-1622.
9. Camacho PM, Petak SM, Brinkley N et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. *Endocr Pract*. 2020;26(1):1-46.
10. LeBoggs MS, Greenspan SL, Insongna KL, et al. Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int*. 2022 Oct;33(10):2049-2102. doi:10.1007/s00198-021-05900-y. Erratum in: *Osteoporos Int*. 2022 Jul 28.
11. Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. *Osteoporos Int* (2014) 25:1439-1443. DOI 10.1007/s00198-014-2655-z.
12. Hodsman AB, Bauder DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. *Endocr Rev*. 2005 Aug;26(5):688-703. Epub 2005 Mar 15.
13. *Male Osteoporosis*
14. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guidelines. *J Clin Endocrinol Metab* 2012;97(6):1802-1822.
15. *Glucocorticoid-Induced Osteoporosis*
16. Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Rheumatol*. 2023 Oct 16. doi:10.1002/art.42646. Epub ahead of print. PMID:37845798.
17. *Oncology*
18. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at [www.nccn.org](http://www.nccn.org). Accessed October 23, 2023 March 13, 2024.

## CLINICAL POLICY

### Denosumab



- ~~13-15.~~ National Comprehensive Cancer Network. Multiple Myeloma Version ~~43.~~2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Accessed ~~October 23,~~March 13, 2023.
- ~~14-16.~~ National Comprehensive Cancer Network. Bone Cancer Version ~~42.~~2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/bone.pdf](https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf). Accessed ~~October 23,~~2023-March 13, 2024.
- ~~15-17.~~ National Comprehensive Cancer Network. Breast Cancer Version ~~4-20232.~~2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed ~~October 23, 2023-~~March 13, 2024.
- ~~16-18.~~ National Comprehensive Cancer Network. Prostate Cancer Version ~~4-20233.~~2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed ~~October 23, 2023-~~March 13, 2024.
- ~~17-19.~~ National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Version ~~4-20233.~~2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed ~~October 23, 2023-~~March 13, 2024.
- ~~18-20.~~ National Comprehensive Cancer Network. Kidney Cancer Version ~~43.~~2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf). Accessed ~~October 23,~~2023-March 13, 2024.
- ~~19-21.~~ National Comprehensive Cancer Network. Systemic Mastocytosis Version ~~4-20232.~~2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/mastocytosis.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mastocytosis.pdf). Accessed ~~October 23, 2023-~~March 13, 2024.
- ~~22.~~ National Comprehensive Cancer Network. Thyroid Carcinoma Version ~~4-20232.~~204. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf). Accessed ~~October 23, 2023-~~March 13, 2024.
- ~~20.~~

Formatted: Font: Bold, Font color: Auto

Formatted: Font: Bold, Font color: Auto

Formatted: Indent: Left: 0.25", No bullets or numbering

### Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0897	Injection, denosumab, 1 mg
<u>Q5136</u>	<u>Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg</u>

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy.	01.21	04.21
Removed Prolia criteria. LDH Prolia criteria utilized for Physician Administered Medication Prior Authorizations. For multiple myeloma or solid tumor and systemic mastocytosis: allowed bypassing of redirection of step therapy in Stage IV or metastatic cancer settings.	04.22	07.01.22

Formatted Table



## CLINICAL POLICY

### Denosumab



Reviews, Revisions, and Approvals	Date	LDH Approval Date
Template changes applied to other diagnoses/indications and continued therapy section. References reviewed and updated. Added blurb this policy is for medical benefit only. Minor grammatical and formatting edits. Updated maximum dosage for MM.	06.27.23	01.03.24
Annual review; no material changes to policy content; appendices updated for clarity, references reviewed and updated.	05.07.24	08.20.24
<a href="#">Added new biosimilars Jubbonti and Wyost to policy; Added HCPCS code [Q5136]. Removal of Appendix E, as LDH Pharmacy has previously clarified that the cancer provisions referenced do not apply to the Medicaid line of business. References reviewed and updated.</a>	10.04.24	

Formatted Table

#### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible

## CLINICAL POLICY

### Denosumab



for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2024 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.